name: Semiquantitative biomechanical assessment (via deformability cytometry), in whole blood, with algorithmic analysis and result reported as an index for viral infection


name: Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, each biomarker reported as present or absent


name: Test for Myxovirus resistance protein A (MxA) and C-reactive protein (CRP) in fingerstick whole blood specimen, each biomarker reported as present or absent


name: Neurofilament light chain (NfL), ultra-sensitive immunoassay, serum or cerebrospinal fluid


name: Ultra-sensitive immunoassay for neurofilament light chain (Nfl) in cerebrospinal fluid


name: Ultra-sensitive immunoassay for neurofilament light chain (Nfl) in serum


name: Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)


name: β-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology


name: Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity


name: Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare


name: Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia), regardless of race or self-identified ancestry, genomic sequence analysis panel, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)


name: Genomic sequence analysis panel that must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2) as a carrier screening for severe inherited conditions such as cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies, alpha thalassemia, regardless of race or self-identified ancestry


name: Genomic sequence analysis panel, carrier screening for severe inherited conditions, must include analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)


name: Testing to detect methylated PENK DNA in urine, reported as likelihood of bladder cancer


name: Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer


name: Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)


name: Testing for cell-free DNA in plasma, reported as the presence or absence of circulating tumor DNA in colorectal cancer


name: Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping (0454U)


name: Testing by optical genome mapping for constitutional/heritable disorders


name: Optical genome mapping for identification of copy number variations, inversions, insertions, translocations, and other structural variants for constitutional/heritable disorders


name: Infectious agents (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or male urine, each pathogen reported as detected or not detected


name: Testing for sexually transmitted infections in vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, or female or male urine, results reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in endocervical specimen, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in female urine, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in gynecological specimen, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in male urine, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in oropharyngeal swab, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in rectal swab, each pathogen reported as detected or not detected


name: Multiplex amplified probe technique for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in vaginal specimen, each pathogen reported as detected or not detected


name: Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative


name: Testing for 9 perfluoroalkyl compounds in plasma or serum


name: Quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) testing for 9 Perfluoroalkyl substance (PFAS) compounds in plasma


name: Quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) testing for 9 Perfluoroalkyl substance (PFAS) compounds in serum


name: Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score


name: Testing for S100A8 and S100A9 in tear fluid with age, reported as a risk score for breast cancer


name: β-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology


name: Testing for β-amyloid and total tau in spinal fluid, ratio reported as positive or negative for amyloid pathology


name: Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes


name: DNA testing of 24 genes in whole blood or saliva in cancer


name: DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes in whole blood, in cancer


name: DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes in whole buccal swab, in cancer


name: Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes


name: Analysis of 24 genes in whole blood or saliva for gene-drug interactions in cancer


name: Pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes in buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes in cancer


name: Pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes in whole blood, with variant analysis, including impacted gene-drug interactions and reported phenotypes in cancer


name: Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary


name: Screening testing of melatonin levels in saliva during sleep study


name: Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker


name: Gene expression profiling of high-risk HPV types in cervical cells, reported as positive or negative for increased risk of abnormal cervical cells or cervical cancer for each type


name: mRNA gene expression by real-time nucleic acid sequence-based amplification (NASBA), profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58) in endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker


name: mRNA gene expression by real-time nucleic acid sequence-based amplification (NASBA), profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58) in exocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker


name: Screening test for DNA markers in stool reported as a positive or negative result for colorectal cancer


name: Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2R5C, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result


name: Oncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative


name: DNA testing for 2 genes reported as a positive or negative result for bladder cancer


name: Cardiology (coronary artery disease [CAD]), DNA, genome-wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease


name: DNA genome study with patient lifestyle and clinical data, using saliva, results reported as a risk for heart disease


name: DNA genome-wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease


name: Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden


name: DNA sequencing of 60 genes in urine, results reported as minimal residual disuse positive or negative and disease burden


name: Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis


name: Testing in serum and whole blood reported as a single score for nonalcoholic steatohepatitis and fibrosis


name: Testing for miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c in serum, algorithm reported as a single score for nonalcoholic steatohepatitis (NASH) activity and fibrosis


name: Testing for miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c in whole blood, algorithm reported as a single score for nonalcoholic steatohepatitis (NASH) activity and fibrosis


name: Rare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination


name: Whole genome sequencing in amniotic fluid, chorionic villus sample, or products of conception, results reported based on phenotype for constitutional/heritable disorders


name: Whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy in amniotic fluid, with identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination for constitutional/heritable disorders


name: Whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy in chorionic villus sample, with identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination for constitutional/heritable disorders


name: Whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy in products of conception, with identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination for constitutional/heritable disorders


name: Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma


name: Next-generation sequencing of 8 DNA targets in plasma for detection of minimal residual disease in head and neck cancer


name: Testing for 35 variants of KRAS and NRAS genes in tissue sample, reported as predictive identification of detected mutations in colorectal cancer


name: Oncology (colorectal cancer), qualitative real-time PCR of 35 variants of KRAS and NRAS genes (exons 2, 3, 4), formalin-fixed paraffin-embedded (FFPE), predictive, identification of detected mutations


name: Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiqualitative, blood, reported as predictive evidence of early Sjögren's syndrome


name: Testing for proteins and antibodies in blood reported as predictive evidence of early Sjögren syndrome


name: Oncology (solid tumor), next-generation sequencing (NGS) of DNA from formalin-fixed paraffin-embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for sequence variants, insertion and deletion alterations, copy number variants, rearrangements, microsatellite instability, and tumor-mutation burden


name: Next-generation sequencing of DNA from tissue sample of 648 genes with comparative sequence analysis from a matched normal blood or saliva specimen in solid tumor cancer


name: Hereditary pan-cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene


name: Next-generation sequencing of 88 genes in blood or saliva, results reported as positive or negative for variants of each gene for hereditary cancers


name: Genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS), Sanger sequencing in whole blood, reported as positive or negative for germline variants for each gene in hereditary pan-cancer


name: Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer


name: Next-generation sequencing of 23 genes reported as pathologic mutations with a genetic risk score for prostate cancer


name: Genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer


name: Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes


name: Pharmacogenomic genotyping of 14 genes including reported phenotypes to evaluate drug metabolism in psychiatric disorders


name: Drug metabolism and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes in buccal swab for psychiatric disorders


name: Drug metabolism and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes in whole blood for psychiatric disorders


name: Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes


name: Pharmacogenomic genotyping of 14 genes including gene-drug interactions and reported phenotypes to evaluate drug metabolism in psychiatric disorders


name: Drug metabolism and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes in buccal swab for psychiatric disorders


name: Drug metabolism and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes in whole blood for psychiatric disorders


name: Oncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET) in formalin-fixed paraffin-embedded (FFPE) tissue, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and reported as actionable detected variants for therapy selection


name: DNA and RNA analysis of 9 genes to determine therapy selection in non-small cell lung cancer


name: Digital PCR DNA analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET), interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements in formalin-fixed paraffin-embedded (FFPE) tissue. reported as actionable detected variants for therapy selection in non-small cell lung cancer


name: Digital PCR RNA analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET), interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements in formalin-fixed paraffin-embedded (FFPE) tissue. reported as actionable detected variants for therapy selection in non-small cell lung cancer


name: Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification


name: DNA and RNA next generation sequencing for identifying pathogens in bacteria, virus, fungal, an parasite infection


name: Metagenomic next-generation DNA sequencing in cerebrospinal fluid (CSF) bioinformatic analysis, with positive pathogen identification in infectious disease


name: Metagenomic next-generation RNA sequencing in cerebrospinal fluid (CSF) bioinformatic analysis, with positive pathogen identification in infectious disease


name: IDH1 (isocitrate dehydrogenase 1 [NADP+]), IDH2 (isocitrate dehydrogenase 2 [NADP+]), and TERT (telomerase reverse transcriptase) promoter (eg, central nervous system [CNS] tumors), next-generation sequencing (single-nucleotide variants [SNV], deletions, and insertions)


name: Next-generation sequencing of genes in central nervous system tumors


name: Obstetrics (preeclampsia), biochemical assay of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), serum, ratio reported for sFlt-1/PlGF, with risk of progression for preeclampsia with severe features within 2 weeks


name: Testing of specific protein and factors to determine risk of progression of preeclampsia


name: Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance


name: Testing for probability of fluoroquinolone resistance in gonorrhea


name: Testing for Neisseria gonorrhoeae, ciprofloxacin resistance (gyrA S91F point mutation) in oral swab, algorithm reported as probability of fluoroquinolone resistance


name: Testing for Neisseria gonorrhoeae, ciprofloxacin resistance (gyrA S91F point mutation) in rectal swab, algorithm reported as probability of fluoroquinolone resistance


name: Testing for Neisseria gonorrhoeae, ciprofloxacin resistance (gyrA S91F point mutation) in vaginal swab, algorithm reported as probability of fluoroquinolone resistance


name: Infectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance


name: Testing for probability of macrolide resistance in in mycoplasma genitalium


name: Testing for Mycoplasma genitalium macrolide sensitivity (23S rRNA point mutation) in oral swab, algorithm reported as probability of macrolide resistance


name: Testing for Mycoplasma genitalium macrolide sensitivity (23S rRNA point mutation) in rectal swab, algorithm reported as probability of macrolide resistance


name: Testing for Mycoplasma genitalium macrolide sensitivity (23S rRNA point mutation) in vaginal swab, algorithm reported as probability of macrolide resistance


name: Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden


name: RNA next-generation sequencing in solid tumor cancer


name: Cell-free DNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden in solid tumor cancer


name: Cell-free RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden in solid tumor cancer


name: Oncology (pan-solid tumor), next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction


name: DNA next-generation sequencing of tumor methylation markers present in cell-free circulating tumor DNA in pan-solid tumor


name: Next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction in solid tumor cancer


name: Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidy-corrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instability


name: Genomic sequence analysis of 84 genes in solid tumors


name: Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected


name: DNA sequence analysis for detection of fetal presence of antigen(s)


name: Cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected


name: Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)


name: Single-gene noninvasive prenatal test to determine fetal risk score for inherited conditions


name: Cell-free DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition


name: Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanoma-associated antigen, CD34 and CD45 protein biomarkers, peripheral blood


name: Testing for antigen and protein biomarkers in melanoma(s)


name: Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of estrogen receptor (ER) protein biomarker-expressing cells, peripheral blood


name: Testing for protein biomarkers and quantification of estrogen receptor protein biomarker expressing cells in solid tumors


name: Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 protein biomarker-expressing cells, peripheral blood


name: Testing for protein biomarkers and quantification of PD-L1 protein biomarker expressing cells in solid tumors


name: Transplantation medicine, quantification of donor-derived cell-free DNA (cfDNA) using next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA


name: Testing of donor-derived cell-free DNA, reported as percentage of donor-derived cell-free DNA to inform likelihood of organ rejection


name: Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative


name: Red blood cell antigen testing in pregnant individuals known to be RhD negative


name: Quantification of donor-derived cell-free DNA (cfDNA) using next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA for fetal RhD gene analysis


name: Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior negative prostate biopsy), algorithm reported as risk of likelihood of detecting clinically significant prostate cancer


name: Analysis of proteins to determine risk of clinically significant prostate cancer


name: Oncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for methylation by real-time RT-PCR, and 4 proteins by enzyme-linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk


name: Analysis of genes and proteins to determine risk of colorectal cancer or advanced adenoma risk


name: Oncology (prostate), mRNA gene-expression profiling by real-time RT-PCR of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a risk score for prostate cancer


name: mRNA gene-expression profiling of 6 genes to determine risk for prostate cancer


name: Oncology (colorectal), next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation


name: Next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes in colorectal cancer


name: Next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes in blood, report of variants and methylation pattern with interpretation in colorectal cancer


name: Next-generation sequencing for mutation detection in 43 genes and methylation pattern in 45 genes in formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation in colorectal cancer


name: Oncology (colorectal and lung), DNA from formalin-fixed paraffin-embedded (FFPE) tissue, next-generation sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection


name: Next-generation sequencing for mutation detection in 8 genes in colorectal cancer and lung cancer


name: Next-generation- DNA sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection from formalin-fixed paraffin-embedded (FFPE) tissue in colorectal cancer


name: Next-generation- DNA sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection from formalin-fixed paraffin-embedded (FFPE) tissue in lung cancer


name: Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis (M41T, M41V, M41L, c.118-2A>C, c.118-1G>C, c.118-9_118-2del, S56F, S621C)


name: Testing for gene mutations in VEXAS syndrome


name: Oncology (colorectal), blood, quantitative measurement of cell-free DNA (cfDNA)


name: Measurement of cell-free DNA in colorectal cancer


name: Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for HPV


name: Testing for high-risk markers in human papillomavirus


name: Neurology (Alzheimer disease), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio) and tau-protein (pTau217, np-tau217, pTau217/np-tau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorithm score reported as likelihood of positive or negative for amyloid plaques


name: Testing for beta-amyloid and tau-protein to determine likelihood for amyloid plaques in Alzheimer disease


name: Testing for detection of 17 pathologic organism for urinary tract infection


name: Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real-time PCR, reported as positive or negative for each organism


name: Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism


name: Detection of 32 pathogenic organisms in vaginal infection


name: Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus


name: Next-generation sequencing of at least 89 genomic regions to determine likelihood of Barrett's esophagus


name: Oncology (ovarian), DNA, whole-genome sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected


name: Whole-genome DNA sequencing for detection of ovarian cancer


name: Whole-genome DNA sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using plasma, algorithm reported as cancer detected or not detected in ovarian cancer


name: Whole-genome DNA sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood, algorithm reported as cancer detected or not detected in ovarian cancer


name: Transplantation medicine, quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection


name: Testing for quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms to determine risk for active transplant rejection


name: Quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs) in plasma, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection in transplantation medicine


name: Quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs) in urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection in transplantation medicine


name: Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection


name: Testing for quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms to determine risk for active transplant rejection


name: Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA whole-transcriptome data, reported as probability of predicted molecular subtype


name: Augmentative algorithmic analysis of 16 genes using previously sequenced RNA data to determine probability of predicted molecular subtype in pancreatic cancer


name: Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug


name: Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of MSI-high (MSI-H)


name: Augmentative algorithmic analysis of digitized whole-slide imaging of tissue features in prostate cancer


name: Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalin-fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of each biomarker


name: Augmentative algorithmic analysis of digitized whole-slide imaging of tissue features reported as increased or decreased probability of each biomarker in prostate cancer


name: Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)


name: Testing for adalimumab levels in patients undergoing adalimumab therapy for irritable bowel disease


name: Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)


name: Testing for infliximab patients undergoing infliximab therapy for irritable bowel disease


name: Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status


name: Pharmacogenomic genotyping of 40 genes reported as metabolizer status for drug metabolism


name: Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications


name: Testing for 80 or more psychoactive drugs or substances, minimally and maximally effective dose of prescribed and non-prescribed medications


name: Liquid chromatography with tandem mass spectrometry (LC-MS/MS) of 80 or more psychoactive drugs or substances in plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications


name: Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications


name: Testing for 90 or more pain and mental health drugs or substances, minimally effective range of prescribed and non-prescribed medications


name: Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LC-MS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation


name: Testing for 110 or more medications for pain, depression, and anxiety, minimally effective range of prescribed, non-prescribed medications, and illicit medications


name: Liquid chromatography with tandem mass spectrometry (LC-MS/MS) of 110 or more drugs or substances in plasma, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation


name: Therapeutic drug monitoring, 200 or more drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications


name: Testing for 200 or more drugs or substances, minimally effective range of prescribed and non-prescribed medications


name: Liquid chromatography with tandem mass spectrometry (LC-MS/MS) o 200 or more drugs or substances in plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications


name: Influenza vaccine, trivalent, derived from cell cultures, antibiotic free, 0.5 mL dosage, for intramuscular use


name: Influenza virus vaccine, H5N8, derived from cell cultures, adjuvanted, for intramuscular use


name: Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use


name: Influenza virus vaccine, quadrivalent (qIRV), mRNA


name: Influenza virus vaccine, quadrivalent (qIRV), mRNA; 30 mcg/0.5 mL dosage, for intramuscular use


name: Influenza virus vaccine, quadrivalent (qIRV), mRNA; 60 mcg/0.5 mL dosage, for intramuscular use


name: Meningococcal pentavalent vaccine, Men B-4C recombinant proteins and outer membrane vesicle and conjugated Men A, C, W, Y-diphtheria toxoid carrier, for intramuscular use


name: Bilateral computerized ophthalmic diagnostic imaging of anterior segment with interpretation and report


name: Bilateral optical coherence tomography (OCT) of anterior segment with interpretation and report


name: Unilateral computerized ophthalmic diagnostic imaging of anterior segment with interpretation and report


name: Unilateral optical coherence tomography (OCT) of anterior segment with interpretation and report


name: Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral


name: Bilateral computerized ophthalmic diagnostic imaging of optic nerve with interpretation and report


name: Bilateral optical coherence tomography (OCT) of optic nerve with interpretation and report


name: Unilateral computerized ophthalmic diagnostic imaging of optic nerve with interpretation and report


name: Unilateral optical coherence tomography (OCT) of optic nerve with interpretation and report


name: Bilateral computerized ophthalmic diagnostic imaging of retina with interpretation and report


name: Bilateral optical coherence tomography (OCT) of retina with interpretation and report


name: Unilateral computerized ophthalmic diagnostic imaging of retina with interpretation and report


name: Unilateral optical coherence tomography (OCT) of retina with interpretation and report


name: Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina, including OCT angiography


name: Imaging of retina with optical coherence tomography angiography


name: Bilateral computerized ophthalmic diagnostic imaging of retina, with OCT angiography, with interpretation and report


name: Bilateral optical coherence tomography (OCT) of retina with, with OCT angiography, interpretation and report


name: Unilateral computerized ophthalmic diagnostic imaging of retina, with OCT angiography, with interpretation and report


name: Unilateral optical coherence tomography (OCT) of retina with, with OCT angiography, interpretation and report


name: Comprehensive electrophysiologic evaluation with transseptal catheterizations, with insertion and repositioning of transseptal electrode catheters, with induction of arrhythmia, right atrial and left ventricular pacing and recording, and intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation


name: Ultrasound of blood flow within brain for atypical blood flow detection with microbubble injection


name: Vasoreactivity study performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)


name: Ultrasound of blood flow withing brain to assess flexibility of vessels


name: Emboli detection without intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)


name: Ultrasound of vessels in brain for detection of blood clots


name: Venous-arterial shunt detection with intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)


name: Detection of abnormal blood flow in brain vessels using ultrasound with microbubble injection


name: Medical genetics and genetic counseling services, each 30 minutes of total time provided by the genetic counselor on the date of the encounter


name: Counseling for genetic testing provided by a genetic counselor, each 30 minutes of total time on the date of encounter


name: Treatment of behavior impacting health in group setting, each additional 15 minutes


name: Administration of seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional


name: Acupuncture with insertion of 1 or more needles, each additional 15 minutes of personal one-on-one contact with the patient


name: Acupuncture with electrical stimulation and insertion of 1 or more needles, each additional 15 minutes of personal one-on-one contact with the patient


name: Non-Face-to-Face Nonphysician Qualified Health Care Professional Services


name: Telephone discussion provided to an established patient by nonphysician professional, 5-10 minutes


name: Telephone assessment and management service provided to an established patient, parent, or guardian by a nonphysician qualified health care professional, 5-10 minutes of medical discussion


name: Telephone discussion provided to an established patient by nonphysician professional, 11-20 minutes


name: Telephone assessment and management service provided to an established patient, parent, or guardian by a nonphysician qualified health care professional, 11-20 minutes of medical discussion


name: Telephone discussion provided to an established patient by nonphysician professional, 21-30 minutes


name: Telephone assessment and management service provided to an established patient, parent, or guardian by a nonphysician qualified health care professional, 21-30 minutes of medical discussion


name: Online digital evaluation and management service provided to an established patient by nonphysician professional for up to 7 days, total time 5-10 minutes


name: Online digital evaluation and management service provided to an established patient by nonphysician professional for up to 7 days, total time 11-20 minutes


name: Remote therapeutic monitoring (eg, therapy adherence, therapy response, digital therapeutic intervention)


name: Set-up and patient education on use of equipment for remote therapeutic monitoring


name: Initial set-up and patient education on use of equipment for remote therapeutic monitoring of digital therapeutic intervention


name: Initial set-up and patient education on use of equipment for remote therapeutic monitoring of therapy adherence


name: Initial set-up and patient education on use of equipment for remote therapeutic monitoring of therapy response


name: Device supply with daily recording for remote therapeutic monitoring of therapy adherence for cognitive behavioral therapy, each 30 days


name: Placement of bone marrow sampling port, including imaging guidance when performed


name: Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance


name: Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL


name: Transperineal laser destruction of benign prostatic enlargement using imaging guidance for prostate volume greater than or equal to 50 mL


name: Automated eye-movement analysis with interpretation and report


name: High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report


name: Injection(s), bone-substitute material for bone and/or soft tissue hardware fixation augmentation, including intraoperative imaging guidance, when performed


name: Injection(s) of bone-substitute material for bone and/or soft tissue hardware fixation augmentation, including intraoperative imaging guidance


name: Implantation of subcutaneous peritoneal ascites pump system, percutaneous, including pump-pocket creation, insertion of tunneled indwelling bladder and peritoneal catheters with pump connections, including all imaging and initial programming, when performed


name: Implantation of subcutaneous peritoneal ascites pump system through the skin, including pump-pocket creation, insertion of tunneled indwelling bladder and peritoneal catheters with pump connections, including all imaging and initial programming


name: Replacement of indwelling bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed


name: Replacement of permanent bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed


name: Revision of a subcutaneously implanted peritoneal ascites pump system, any component (ascites pump, associated peritoneal catheter, associated bladder catheter), including imaging and programming, when performed


name: Removal of a peritoneal ascites pump system, including implanted peritoneal ascites pump and indwelling bladder and peritoneal catheters


name: Removal of a peritoneal ascites pump system, including implanted peritoneal ascites pump and permanent bladder and peritoneal catheters


name: Programming of subcutaneously implanted peritoneal ascites pump system by physician or other qualified health care professional


name: Duplex scan of hemodialysis fistula, computer-aided, limited (volume flow, diameter, and depth, including only body of fistula)


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission


name: Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report


name: Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to treatment, and removal of the oral device


name: Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes


name: Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; initial nerve (List separately in addition to code for primary procedure)


name: Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; each additional nerve (List separately in addition to code for primary procedure)


name: Esophagoscopy, flexible, transoral, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for esophageal stricture, including fluoroscopic guidance, when performed


name: Colonoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed


name: Sigmoidoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed


name: End-tidal control of inhaled anesthetic agents and oxygen to assist anesthesia care delivery (List separately in addition to code for primary procedure)


name: Non-thermal destruction via acoustic energy delivery to malignant renal tissue, including imaging guidance


name: Personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold-starting location, neuronavigation files and target report, review and interpretation


name: Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day


name: Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day


name: Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day


name: Noninvasive assessment of blood oxygenation, gas exchange efficiency, and cardiorespiratory status, with physician or other qualified health care professional interpretation and report


name: Cannulation of the liver allograft in preparation for connection to the normothermic perfusion device and decannulation of the liver allograft following normothermic perfusion


name: Insertion of a tube into the liver allograft in preparation for connection to the normothermic perfusion device and removal of the tube from the liver allograft following normothermic perfusion


name: Connection of liver allograft to normothermic machine perfusion device, hemostasis control


name: Connection of liver allograft to normothermic machine perfusion device, hemostasis control; initial 4 hours of monitoring time, including hourly physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment)


name: Connection of liver allograft to normothermic machine perfusion device, blood clotting control; initial 4 hours of monitoring time, including hourly physiological and laboratory assessments


name: Connection of liver allograft to normothermic machine perfusion device, hemostasis control; each additional hour, including physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment) (List separately in addition to code for primary procedure)


name: Connection of liver allograft to normothermic machine perfusion device, blood clotting control; each additional hour, including physiological and laboratory assessments


name: Noninvasive augmentative arrhythmia analysis derived from quantitative computational cardiac arrhythmia simulations, based on selected intervals of interest from 12-lead electrocardiogram and uploaded clinical parameters, including uploading clinical parameters with interpretation and report


name: Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report


name: Noninvasive determination of absolute quantitation of myocardial blood flow (AQMBF), derived from augmentative algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)


name: Noninvasive estimate of absolute quantitation of myocardial blood flow (AQMBF), derived from assistive algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)


name: QTc interval derived by augmentative algorithmic analysis of input from an external, patient-activated mobile ECG device


name: Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG


name: Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; with interpretation and report


name: Algorithmically generated 12-lead ECG from a reduced-lead ECG


name: Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; tracing only


name: Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; interpretation and report only


name: Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care


name: Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; first application, total wound(s) surface area less than or equal to 50 sq cm


name: Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; each additional application, total wound(s) surface area less than or equal to 50 sq cm (List separately in addition to code for primary procedure)


name: Open implantation of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed


name: Implantation of integrated vagus nerve neurostimulator


name: Replacement of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed


name: Replacement of integrated vagus nerve neurostimulator


name: Removal of integrated neurostimulation system, vagus nerve


name: electronic analysis of implanted integrated neurostimulation system, vagus nerve


name: Electronic analysis of implanted integrated neurostimulation system, vagus nerve; without programming by physician or other qualified health care professional


name: Electronic analysis of implanted integrated vagus nerve neurostimulator without programming


name: Electronic analysis of implanted integrated neurostimulation system, vagus nerve; with simple programming by physician or other qualified health care professional


name: Electronic analysis of implanted integrated vagus nerve neurostimulator with simple programming


name: Transcatheter Therapeutic Drug Delivery by Intracoronary Drug-Delivery Balloon


name: Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting), including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch


name: Transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon, with imaging supervision, interpretation, and report, performed on a single major coronary artery or branch


name: Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting) performed on a separate target lesion from the target lesion treated with balloon angioplasty, coronary stent placement or coronary atherectomy, including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch (List separately in addition to code for percutaneous coronary stent or atherectomy intervention)


name: Transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon, performed on a separate target lesion from the target lesion treated with balloon angioplasty, coronary stent placement or coronary atherectomy


name: Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters


name: Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator and dual transvenous electrodes/leads (pacing and defibrillation)


name: Insertion of permanent cardiac contractility modulation-defibrillation system component(s), pulse generator and dual transvenous electrodes/leads


name: Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator only


name: Insertion of permanent cardiac contractility modulation-defibrillation system component(s), pulse generator only


name: Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; single transvenous lead (pacing or defibrillation) only


name: Insertion of permanent cardiac contractility modulation-defibrillation system component(s), single transvenous lead only


name: Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; dual transvenous leads (pacing and defibrillation) only


name: Insertion of permanent cardiac contractility modulation-defibrillation system component(s), dual transvenous leads only


name: Removal of a permanent cardiac contractility modulation-defibrillation system component(s)


name: Removal of a permanent cardiac contractility modulation-defibrillation system component(s); pulse generator only


name: Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous pacing lead only


name: Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous defibrillation lead only


name: Removal of a permanent cardiac contractility modulation-defibrillation system component(s); dual (pacing and defibrillation) transvenous leads only


name: Removal and replacement of permanent cardiac contractility modulation-defibrillation pulse generator only


name: Repositioning of previously implanted cardiac contractility modulation-defibrillation transvenous electrode(s)/lead(s), including fluoroscopic guidance and programming of sensing and therapeutic parameters


name: Repositioning of previously implanted cardiac contractility modulation-defibrillation transvenous electrode(s)/lead(s)


name: Relocation of skin pocket for implanted cardiac contractility modulation-defibrillation pulse generator


name: Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation-defibrillation system


name: In person programming device evaluation with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis


name: Interrogation device evaluation (in person) with analysis, review, and report, including connection, recording, and disconnection, per patient encounter, implantable cardiac contractility modulation-defibrillation system


name: In person interrogation device evaluation of implantable cardiac contractility modulation-defibrillation system with analysis, review, and report, per patient encounter


name: Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system with interim analysis and report(s) by a physician or other qualified health care professional


name: Remote interrogation device evaluation, up to 90 days, cardiac contractility modulation-defibrillation system with interim analysis and report(s)


name: Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system, remote data acquisition(s), receipt of transmissions, technician review, technical support, and distribution of results


name: Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), at time of initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator


name: Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, at time of initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator


name: Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), separate from initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator


name: Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, separate from initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator


name: Noninvasive detection of heart failure derived from augmentative analysis of an echocardiogram that demonstrated preserved ejection fraction, with interpretation and report by a physician or other qualified health care professional


name: Detection of heart failure derived from augmentative analysis of an echocardiogram that demonstrated preserved ejection fraction


name: Transcatheter implantation of wireless left atrial pressure sensor for long-term left atrial pressure monitoring, including sensor calibration and deployment, right heart catheterization, transseptal puncture, imaging guidance, and radiological supervision and interpretation


name: Transcatheter implantation of wireless left atrial pressure sensor for long-term left atrial pressure monitoring


name: Remote monitoring of a wireless left atrial pressure sensor for up to 30 days, including data from daily uploads of left atrial pressure recordings, interpretation(s) and trend analysis, with adjustments to the diuretics plan, treatment paradigm thresholds, medications or lifestyle modifications, when performed, and report(s) by a physician or other qualified health care professional


name: Remote monitoring of a wireless left atrial pressure sensor for up to 30 days


name: Cystourethroscopy with renal pelvic sympathetic denervation, radiofrequency ablation, retrograde ureteral approach, including insertion of guide wire, selective placement of ureteral sheath(s) and multiple conformable electrodes, contrast injection(s), and fluoroscopy, bilateral


name: Bladder exam using a flexible scope with renal pelvic sympathetic denervation using heat


name: Photobiomodulation therapy of retina, single session


name: External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage


name: External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; including recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional


name: External electrocardiographic recording for more than 15 days up to 30 days by continuous rhythm recording and storage


name: External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; recording (including connection and initial recording)


name: External electrocardiographic recording for more than 15 days up to 30 days by continuous rhythm recording and storage; recording


name: External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; scanning analysis with report


name: External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional


name: Cystourethroscopy, flexible; with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization


name: Cystourethroscopy, flexible; with removal and replacement of prostatic urethral scaffold


name: Bladder exam of a flexible scope with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization


name: Cystourethroscopy, flexible; with removal of prostatic urethral scaffold


name: 3D contour simulation of target liver lesion(s) and margin(s) for image-guided percutaneous microwave ablation


name: Intraoperative assessment for abnormal (tumor) tissue, in-vivo, following partial mastectomy (eg, lumpectomy) using computer-aided fluorescence imaging (List separately in addition to code for primary procedure)


name: Assessment for abnormal tissue, during surgery following partial mastectomy using computer-aided fluorescence imaging


name: Orthopedic implant movement analysis using paired computed tomography (CT) examination of the target structure, including data acquisition, data preparation and transmission, interpretation and report (including CT scan of the joint or extremity performed with paired views)


name: Orthopedic implant movement analysis using paired CT examination of the target structure


name: Magnetic resonance image guided low intensity focused ultrasound (MRgFUS), stereotactic blood-brain barrier disruption using microbubble resonators to increase the concentration of blood-based biomarkers of target, intracranial, including stereotactic navigation and frame placement, when performed


name: Intracranial magnetic resonance image guided low intensity focused ultrasound, stereotactic blood-brain barrier disruption using microbubble resonators to increase the concentration of blood-based biomarkers of target


name: Oncology (central nervous system), analysis of 30,000 DNA methylation loci by methylation array, utilizing DNA extracted from tumor tissue, diagnostic algorithm reported as probability of matching a reference tumor subclass


name: Analysis of DNA from tumor tissue with results reported as probability of matching a reference tumor subclass in brain and spinal cord cancer


name: Telemedicine: Synchronous Audio-Video E/M Services (New Patient) (Add-on Table)


name: Telemedicine: Synchronous Audio-Video E/M Services (Established Patient) (Add-on Table)


name: Telemedicine: Synchronous Audio-Only E/M Services (New Patient) (Add-on Table)


name: Telemedicine: Synchronous Audio-Only E/M Services (Established Patient) (Add-on Table)


name: 80% Abamectin Component B1A / 20% Abamectin Component B1B


name: Automated analysis of binocular eye movements without spatial calibration, including disconjugacy, saccades, and pupillary dynamics for the assessment of concussion, with interpretation and report


name: Replacement of a subcutaneous peritoneal ascites pump, including reconnection between pump and indwelling bladder and peritoneal catheters, including initial programming and imaging, when performed


name: Intrauterine contraceptive device fitted (finding)


name: Clinical Trial Randomization Programming Documentation


name: Clinical Trial Randomization Validation Documentation


name: Clinical Trial Statistical Analysis Plan Documentation


name: Retained Biospecimen Contains DNA Indicator


name: Impurities/Degradation Products/Related Substances Test


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Question Clinical Classification Original Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Question Clinical Classification Standardized Character Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0102 Question Clinical Classification Original Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0102 Question Clinical Classification Standardized Character Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Question Clinical Classification Original Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Question Clinical Classification Standardized Character Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Question Clinical Classification Original Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Question Clinical Classification Standardized Character Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0105 Question Clinical Classification Original Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0105 Question Clinical Classification Standardized Character Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Question Clinical Classification Original Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Question Clinical Classification Standardized Character Response


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Original Result - >= 400


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Original Result - < 400


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Original Result - < 300


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Original Result - < 200 with respiratory support (mechanical ventilation including CPAP)


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Original Result - < 100 with respiratory support (mechanical ventilation including CPAP)


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Standardized Character Result 0


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Standardized Character Result 1


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Standardized Character Result 2


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Standardized Character Result 3


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0101 Standardized Character Result 4


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0102 Original Result - < 100


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0102 Original Result - < 50


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0102 Original Result - < 20


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Original Result - < 1.2; < 20


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Original Result - 1.2 - 1.9; 20 - 32


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Original Result - 2.0 - 5.9; 33 - 101


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Original Result - 6.0 - 11.9; 102 - 204


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Original Result - > 12.0; > 204


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Standardized Character Result 0


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Standardized Character Result 1


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Standardized Character Result 2


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Standardized Character Result 3


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0103 Standardized Character Result 4


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Original Result - MAP >= 70


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Original Result - MAP < 70


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Original Result - Dopamine <= 5; Dobutamine (any dose)


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Original Result - Dopamine > 5; Epinephrine <= 0.1; Norepinephrine <= 0.1


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Original Result - Dopamine > 15; Epinephrine > 0.1; Norepinephrine > 0.1


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Standardized Character Result 0


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Standardized Character Result 1


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Standardized Character Result 2


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Standardized Character Result 3


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0104 Standardized Character Result 4


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Original Result - < 1.2; < 110


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Original Result - 1.2 - 1.9; 110 - 170


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Original Result - 2.0 - 3.4; 171 - 299


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Original Result -3.5 - 4.9; 300 - 440; < 500


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Original Result - > 5; > 440; < 200


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Standardized Character Result 0


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Standardized Character Result 1


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Standardized Character Result 2


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Standardized Character Result 3


name: Sepsis-related Organ Failure Assessment 27th March 2024 Version SOFA0106 Standardized Character Result 4


name: SOFA 27th March 2024 Version - Total SOFA Score


name: Comedo, Solid, Cribriform, Micropapillary


name: Curcuma zedoaria/Cyperus rotundus/Astragalus membranaceus/Notopterygium incisum-based Herbal Supplement


name: Frankincense/Orange/Litsea/Thyme/Clove/Summer Savory/Niaouli/Lemongrass Essential Oil


name: Myelodysplastic Syndrome Overall Response Rate


name: Myelodysplastic Syndrome Complete Response Equivalent


name: Myelodysplastic Syndrome Complete Response with Limited Count Recovery


name: Cell and Gene Therapy Product Characterization Assay


name: Dose Orifice Diameter Drilled Measurement


name: In Process Control Content Uniformity Tests


name: In Vitro or In Vivo Test for Viral Contaminants


name: Individual Substance Fill Weight Measurement


name: Single or Double Drilled Side Assessment


name: Target Group Product Weight Gain Percentage


name: Total Product Impurity above Threshold Assay


name: Unspecified Product Impurity below ICH Identification Threshold


name: Measurable Residual Disease Response Finding


name: Hospice and Palliative Care Anesthesiologist


name: Neuromusculoskeletal and Osteopathic Manipulative Medicine Doctor


name: Blood and Marrow Transplant Clinical Trials Network


name: PD-L1 Tumor Proportion Score Less than 1


name: PD-L1 Tumor Proportion Score Greater than or Equal to 50


name: Emergency Medical Palliative Care Physician


name: Adult Congenital Heart Disease Internist


name: Advanced Heart Failure and Transplant Cardiology Internist


name: Advanced Heart Failure and Transplant Internist


name: Nuclear Medicine Nuclear Imaging and Therapy Specialist


name: Ophthalmology Cornea and External Diseases Specialist


name: Ophthalmology Ophthalmic Plastic and Reconstructive Surgery Specialist


name: Ophthalmology Pediatric Ophthalmology and Strabismus Specialist


name: Ophthalmology Uveitis and Ocular Inflammatory Disease Specialist


name: Internal Medicine Adult Congenital Heart Disease Specialist


name: Internal Medicine Clinical and Laboratory Immunologist


name: Internal Medicine Hypertension Specialist


name: Internal Medicine Obesity Medicine Specialist


name: Internal Medicine Sleep Medicine Specialist


name: Internal Medicine Transplant Hepatology Specialist


name: Internal Medicine Addiction Medicine Specialist


name: Internal Medicine Adolescent Medicine Specialist


name: Emergency Medicine Undersea and Hyperbaric Medicine Specialist


name: Family Medicine Obesity Medicine Specialist


name: Family Medicine Sleep Medicine Specialist


name: Obstetrics and Gynecology Complex Family Planning Specialist


name: Obstetrics and Gynecology Female Pelvic Medicine and Reconstructive Surgery Specialist


name: Obstetrics and Gynecology Hospice and Palliative Medicine Specialist


name: Obstetrics and Gynecology Maternal and Fetal Medicine Specialist


name: Obstetrics and Gynecology Obesity Medicine Specialist


name: Average Fill Substance Weight Measurement


name: Complete Remission in Myelodysplastic Syndrome with Partial Hematologic Recovery


name: Full Scale Intelligence Quotient (WAIS-IV)


name: Intraperitoneal Carboplatin/Paclitaxel/Intraperitoneal Paclitaxel Regimen


name: PSMA-Positive Extracellular Vesicles High


name: PSMA-Positive Extracellular Vesicles Low


name: Otolaryngology Plastic Surgery within the Head and Neck


name: Otology and Neurotology Otolaryngologist


name: Otolaryngologist, Facial Plastic Surgery


name: Cisplatin Followed by Carboplatin/Paclitaxel Regimen


name: Clinical Pathology and Laboratory Medicine Pathologist


name: Clinical & Laboratory Immunology Pediatrician


name: Hospice and Palliative Medicine Physiatrist


name: Plastic Surgery within the Head and Neck Plastic Surgeon


name: Blood Banking & Transfusion Medicine Pathologist


name: Preventive Medicine Obesity Medicine Physician


name: Preventive Medicine Addiction Medicine Physician


name: Preventive Medicine Clinical Informatics Physician


name: Preventive Medicine Preventive Medicine/Occupational Environmental Medicine Physician


name: PSA Level Greater than or Equal to Eight


name: Psychiatrist or Neurologist Addiction Medicine Physician


name: Psychiatrist or Neurologist Obesity Medicine Physician


name: Online Adaptive Proton Stereotactic Body Radiation Therapy


name: Psychiatrist or Neurologist Diagnostic Neuroimaging Physician


name: Bevacizumab/Carboplatin/Docetaxel Followed by Bevacizumab Regimen


name: Respiratory Tract Route of Administration


name: Bevacizumab/Docetaxel/Oxaliplatin Followed by Bevacizumab Regimen


name: Psychiatrist or Neurologist Behavioral Neurology and Neuropsychiatry Physician


name: Psychiatrist or Neurologist Hospice and Palliative Medicine Physician


name: Psychiatrist or Neurologist Brain Injury Physician


name: Psychiatrist or Neurologist Pain Medicine Physician


name: Psychiatrist or Neurologist Sports Medicine Physician


name: Psychiatrist or Neurologist Sleep Medicine Physician


name: Hospice and Palliative Medicine Radiologist


name: Female Pelvic Medicine and Reconstructive Surgery Urologist


name: Environmental Modification Occupational Therapy Assistant


name: Feeding, Eating and Swallowing Occupational Therapy Assistant


name: Low Vision Occupational Therapy Assistant


name: Driving and Community Mobility Occupational Therapy Assistant


name: PD-L1 Expression Greater than 50 Percent


name: PQ/CMC Substance Classification Terminology


name: MYC Gene Rearrangement and BCL2 Gene Rearrangement Positive


name: MYC Gene Rearrangement and BCL6 Gene Rearrangement Positive


name: MYC Gene Rearrangement, BCL2 Gene Rearrangement, and BCL6 Gene Rearrangement Positive


name: Clinical Electrophysiologic Physical Therapist


name: Adults Cut Meal Size or Skipped Meals Because Not Enough Money Question


name: Ate Less Than Should Because Not Enough Money Question


name: Hungry and Didn't Eat Because Couldn't Afford Food Question


name: Intravesical Nogapendekin Alfa Inbakicept/BCG Regimen


name: Delayed Medical Care Due to Cost Question


name: Did Not Get Medical Care Due to Cost Question


name: How Often Visited Urgent Care Center or Drug/Grocery Store Clinic About Health Question


name: Regimen Used to Treat Histiocytic and Dendritic Cell Neoplasm


name: Pulmonary Diagnostics Respiratory Therapist


name: Pulmonary Rehabilitation Respiratory Therapist


name: Pulmonary Function Technologist Respiratory Therapist


name: Skilled Nursing Facility/Subacute Care Respiratory Therapist


name: Registered Geriatric Respiratory Therapist


name: Registered Skilled Nursing Facility/Subacute Care Respiratory Therapist


name: Environmental Modification Occupational Therapist


name: Feeding, Eating & Swallowing Occupational Therapist


name: Orientation and Mobility Training Provider Rehabilitation Counselor


name: Doxorubicin/Ifosfamide Alternating with Cisplatin/Etoposide Regimen


name: PD-L1 Combined Positive Score Greater than or Equal to 10


name: Pathology Hemapheresis Practitioner Specialist Technologist


name: Pathology Medical Technologist Specialist Technologist


name: Unable to Obtain Basic Essentials Question


name: Higher Incidence and/or Prevalence of Disease Question


name: Premature or Excessive Mortality from Specific Health Conditions Question


name: Greater Global Burden of Disease Question


name: Poorer Health Behaviors and/or Clinical Outcomes Question


name: Worse Outcomes on Validated Self-reported Measures Question


name: Health Information Coding Specialist, Physician Office Based Specialist Technologist


name: Health Information Coding Specialist, Hospital Based Specialist Technologist


name: Registered Health Information Record Administrator Specialist Technologist


name: Health Information Assistant Record Technician


name: Biomedical Engineering Specialist Technologist


name: Biomedical Photographer Specialist Technologist


name: Surgical Assistant Specialist Technologist


name: Graphics Methods Specialist Technologist


name: Non-Physician Clinical Pathology Laboratory Director


name: Developmentally Disabled Services, Day Training


name: Medical Geneticist Specialist Technologist


name: Medical Illustration Specialist Technologist


name: Orthopedic Assistant Specialist Technologist


name: Exhaled Carbon Monoxide Concentration Less than 5 ppm


name: Program of All-Inclusive Care for the Elderly Provider Organization


name: Marked Reduction or Absence of Erythroid Precursors in the Bone Marrow


name: No Evidence of Gastrointestinal Polyps Present


name: Full Scale Intelligence Quotient (WISC-V)


name: Mental Health Clinical Nurse Specialist for the Chronically Ill


name: Geropsychiatric Clinical Nurse Specialist


name: Student Enrolled in Organized Health Care Program


name: Physician Assistant Surgical Technologist


name: PRO-CTCAE Measurement System Terminology


name: PRO-CTCAE Version 1.0 Questionnaire Terminology


name: Ped-PRO-CTCAE Version 1.0 Questionnaire Terminology


name: PRO-CTCAE Oral Adverse Event Terminology


name: PRO-CTCAE Gastrointestinal Adverse Event Terminology


name: PRO-CTCAE Respiratory Adverse Event Terminology


name: PRO-CTCAE Cardiovascular Adverse Event Terminology


name: PRO-CTCAE Cutaneous Adverse Event Terminology


name: PRO-CTCAE Neurological Adverse Event Terminology


name: PRO-CTCAE Visual or Perceptual Alteration Adverse Event Terminology


name: PRO-CTCAE Alteration in Attention or Memory Adverse Event Terminology


name: PRO-CTCAE Pain Adverse Event Terminology


name: PRO-CTCAE Alteration in Sleep or Wakefulness Adverse Event Terminology


name: PRO-CTCAE Mood Alteration Adverse Event Terminology


name: PRO-CTCAE Genitourinary Adverse Event Terminology


name: PRO-CTCAE Sexual Adverse Event Terminology


name: PRO-CTCAE Miscellaneous Adverse Event Terminology


name: Ped-PRO-CTCAE Oral Adverse Event Terminology


name: Ped-PRO-CTCAE Gastrointestinal Adverse Event Terminology


name: Ped-PRO-CTCAE Respiratory Adverse Event Terminology


name: Ped-PRO-CTCAE Cardiovascular Adverse Event Terminology


name: Ped-PRO-CTCAE Cutaneous Adverse Event Terminology


name: Ped-PRO-CTCAE Neurological Adverse Event Terminology


name: Ped-PRO-CTCAE Visual or Perceptual Alteration Adverse Event Terminology


name: Ped-PRO-CTCAE Alteration in Attention or Memory Adverse Event Terminology


name: Ped-PRO-CTCAE Pain Adverse Event Terminology


name: Ped-PRO-CTCAE Alteration in Sleep or Wakefulness Adverse Event Terminology


name: Ped-PRO-CTCAE Mood Alteration Adverse Event Terminology


name: Ped-PRO-CTCAE Genitourinary Adverse Event Terminology


name: Ped-PRO-CTCAE Miscellaneous Adverse Event Terminology


name: Ped-PRO-CTCAE Attribute Value Terminology


name: PRO-CTCAE Gastrointestinal Adverse Event


name: PRO-CTCAE Visual or Perceptual Alteration Adverse Event


name: PRO-CTCAE Alteration in Attention or Memory Adverse Event


name: PRO-CTCAE Alteration in Sleep or Wakefulness Adverse Event


name: Ped-PRO-CTCAE Gastrointestinal Adverse Event


name: Ped-PRO-CTCAE Cardiovascular Adverse Event


name: Ped-PRO-CTCAE Neurological Adverse Event


name: Ped-PRO-CTCAE Visual or Perceptual Alteration Adverse Event


name: Ped-PRO-CTCAE Alteration in Attention or Memory Adverse Event


name: Ped-PRO-CTCAE Alteration in Sleep or Wakefulness Adverse Event


name: Ped-PRO-CTCAE Mood Alteration Adverse Event


name: Ped-PRO-CTCAE Genitourinary Adverse Event


name: Ped-PRO-CTCAE Miscellaneous Adverse Event


name: TACSTD2 Expression by Immunohistochemistry 1+


name: Cracking at the Corners of the Mouth (Cheilosis/Cheilitis), PRO-CTCAE


name: Irregular Periods/Vaginal Bleeding, PRO-CTCAE


name: Missed Expected Menstrual Period, PRO-CTCAE


name: Difficulty Achieving and Maintaining Erection, PRO-CTCAE


name: Breast Swelling and Tenderness, PRO-CTCAE


name: Pain and Swelling at Injection Site, PRO-CTCAE


name: Change in Usual Urine Color, Ped-PRO-CTCAE


name: Neutrophil Count Greater than 0.5x10^9/L


name: PD-L1 Tumor Proportion Score Greater than 1


name: Extraocular Sebaceous Carcinoma Molecular Subtypes


name: Neoplastic Fibroepithelial Cell Proliferation


name: Intratracheal Route of Administration (functional concept)


name: Endometrial Cancer with Molecular Classification by FIGO Stage 2023


name: Endometrial Carcinoma Molecular Subtypes


name: Molecular Classification FIGO 2023 Stage


name: Estrogen Receptor Positive by Immunohistochemistry Less than or Equal to 10 Percent


name: Progesterone Receptor Positive by Immunohistochemistry Less than or Equal to 10 Percent


name: Cancer DNA to Total Tumor Tissue DNA Ratio Measurement


name: Subclonal Genome to Total Tumor Tissue Genome Ratio Measurement


name: Within 2 Months After Completion of First-Course Treatment


name: GeneChip Human Genome U133 Plus 2.0 Array


name: Hormone Replacement Therapy Status Indicator


name: Papillary Renal Cell Carcinoma Type Indicator


name: Aligned Read Coverage Greater than or Equal to 150x


name: Menopause-specific Quality of Life Questionnaire


name: Bothered by Dissatisfaction with Personal Life Question


name: Bothered by Being Impatient with Other People Question


name: Bothered by Feelings of Wanting to Be Alone Question


name: Bothered by Flatulence or Gas Pain Question


name: Bothered by Aching in Muscles and Joints Question


name: Bothered by Feeling Tired or Worn Out Question


name: Bothered by Aches in Back of Neck or Head Question


name: Bothered by Decrease in Physical Strength Question


name: Bothered by Decrease in Stamina Question


name: Bothered by Increased Facial Hair Question


name: Bothered by Changes in Appearance, Texture, or Tone of Skin Question


name: Bothered by Involuntary Urination when Laughing or Coughing Question


name: Bothered by Change In Sexual Desire Question


name: Bothered by Vaginal Dryness During Intercourse Question


name: Bothered by Anxiety or Nervousness Question


name: Problem Identified Before Clinical Use/Exposure


name: Breast DCIS, Resection CAP Synoptic Pathology Report


name: Breast DCIS, Biopsy CAP Synoptic Pathology Report


name: Breast Phyllodes Tumor CAP Synoptic Pathology Report


name: Breast Invasive Carcinoma, Resection CAP Synoptic Pathology Report


name: Breast Invasive Carcinoma, Biopsy CAP Synoptic Pathology Report


name: Breast Carcinoma Biomarker Reporting CAP Synoptic Pathology Report


name: Central Nervous System Neoplasm CAP Synoptic Pathology Report


name: Adrenal Gland Cancer CAP Synoptic Pathology Report


name: Appendix NET CAP Synoptic Pathology Report


name: Duodenum and Ampulla of Vater NET CAP Synoptic Pathology Report


name: Jejunum and Ileum NET CAP Synoptic Pathology Report


name: Pancreas NET CAP Synoptic Pathology Report


name: Stomach NET CAP Synoptic Pathology Report


name: Thyroid Cancer CAP Synoptic Pathology Report


name: Thyroid Cancer Biomarker Reporting CAP Synoptic Pathology Report


name: Ampulla of Vater Cancer CAP Synoptic Pathology Report


name: Anus Cancer, Excision CAP Synoptic Pathology Report


name: Anus Cancer, Resection CAP Synoptic Pathology Report


name: Appendix Cancer CAP Synoptic Pathology Report


name: Colon and Rectum Cancer, Biopsy CAP Synoptic Pathology Report


name: Colon and Rectum Cancer, Resection CAP Synoptic Pathology Report


name: Colon and Rectum Cancer Biomarker Reporting CAP Synoptic Pathology Report


name: Distal Extrahepatic Bile Ducts Cancer CAP Synoptic Pathology Report


name: Esophagus Cancer CAP Synoptic Pathology Report


name: Gallbladder Cancer CAP Synoptic Pathology Report


name: GIST, Biopsy CAP Synoptic Pathology Report


name: GIST, Resection CAP Synoptic Pathology Report


name: GIST Biomarker Reporting CAP Synoptic Pathology Report


name: Hepatocellular Carcinoma CAP Synoptic Pathology Report


name: Intrahepatic Bile Ducts Carcinoma CAP Synoptic Pathology Report


name: Exocrine Pancreas Cancer CAP Synoptic Pathology Report


name: Perihilar Bile Ducts Cancer CAP Synoptic Pathology Report


name: Small Intestine Cancer CAP Synoptic Pathology Report


name: Stomach Cancer CAP Synoptic Pathology Report


name: Stomach Cancer HER2 Biomarker Reporting CAP Synoptic Pathology Report


name: Kidney Cancer, Biopsy CAP Synoptic Pathology Report


name: Kidney Cancer, Resection CAP Synoptic Pathology Report


name: Penis Cancer CAP Synoptic Pathology Report


name: Prostate Cancer, Needle Biopsy Specimen Level CAP Synoptic Pathology Report


name: Prostate Cancer, Resection CAP Synoptic Pathology Report


name: Prostate Cancer, TURP CAP Synoptic Pathology Report


name: Testis Cancer, Radical Orchiectomy CAP Synoptic Pathology Report


name: Testis Cancer, Lymphadenectomy CAP Synoptic Pathology Report


name: Ureter, Renal Pelvis Cancer, Biopsy CAP Synoptic Pathology Report


name: Ureter, Renal Pelvis Cancer, Resection CAP Synoptic Pathology Report


name: Urethra Cancer, Biopsy CAP Synoptic Pathology Report


name: Urethra Cancer, Resection CAP Synoptic Pathology Report


name: Urinary Bladder Cancer, Resection CAP Synoptic Pathology Report


name: Urinary Bladder Cancer, Biopsy CAP Synoptic Pathology Report


name: Endometrium Cancer CAP Synoptic Pathology Report


name: Gynecologic Cancer Biomarker Reporting CAP Synoptic Pathology Report


name: Ovary, Fallopian Tube, or Peritoneum Cancer CAP Synoptic Pathology Report


name: Trophoblastic Tumors CAP Synoptic Pathology Report


name: Uterine Cervix Cancer, Excision CAP Synoptic Pathology Report


name: Uterine Cervix Cancer, Resection CAP Synoptic Pathology Report


name: Uterine Sarcoma CAP Synoptic Pathology Report


name: Vagina Cancer, Biopsy CAP Synoptic Pathology Report


name: Vagina Cancer, Resection CAP Synoptic Pathology Report


name: Vulva Cancer CAP Synoptic Pathology Report


name: Larynx Cancer CAP Synoptic Pathology Report


name: Oral Cavity Cancer CAP Synoptic Pathology Report


name: Major Salivary Glands Cancer CAP Synoptic Pathology Report


name: Nasal Cavity and Paranasal Sinuses Cancer CAP Synoptic Pathology Report


name: Pharynx Cancer CAP Synoptic Pathology Report


name: Head and Neck Cancer Biomarker Reporting CAP Synoptic Pathology Report


name: Cutaneous Squamous Cell Carcinoma CAP Synoptic Pathology Report


name: Precursor and Mature Lymphoid Malignancies CAP Synoptic Pathology Report


name: Myeloid and Mixed/Ambiguous Lineage Neoplasms CAP Synoptic Pathology Report


name: Plasma Cell Malignancies CAP Synoptic Pathology Report


name: Retinoblastoma CAP Synoptic Pathology Report


name: Uveal Melanoma CAP Synoptic Pathology Report


name: Ewing Sarcoma, Resection CAP Synoptic Pathology Report


name: Ewing Sarcoma, Biopsy CAP Synoptic Pathology Report


name: Germ Cell Tumor, Resection CAP Synoptic Pathology Report


name: Germ Cell Tumor, Biopsy CAP Synoptic Pathology Report


name: Hepatoblastoma, Resection CAP Synoptic Pathology Report


name: Hepatoblastoma, Biopsy CAP Synoptic Pathology Report


name: Neuroblastoma, Resection CAP Synoptic Pathology Report


name: Neuroblastoma, Biopsy CAP Synoptic Pathology Report


name: Rhabdomyosarcoma, Resection CAP Synoptic Pathology Report


name: Rhabdomyosarcoma, Biopsy CAP Synoptic Pathology Report


name: Wilms Tumor, Resection CAP Synoptic Pathology Report


name: Wilms Tumor, Biopsy CAP Synoptic Pathology Report


name: Invasive Melanoma of The Skin, Biopsy CAP Synoptic Pathology Report


name: Invasive Melanoma of The Skin, Excision, Re-Excision CAP Synoptic Pathology Report


name: Melanoma Biomarker Reporting CAP Synoptic Pathology Report


name: Merkel Cell Carcinoma CAP Synoptic Pathology Report


name: Lung Cancer, Resection CAP Synoptic Pathology Report


name: Lung Cancer, Biomarker Reporting CAP Synoptic Pathology Report


name: Pleural Mesothelioma CAP Synoptic Pathology Report


name: Thymus Neoplasm CAP Synoptic Pathology Report


name: Bone Cancer, Biopsy CAP Synoptic Pathology Report


name: Bone Cancer, Resection CAP Synoptic Pathology Report


name: Soft Tissue Cancer, Biopsy CAP Synoptic Pathology Report


name: Soft Tissue Cancer, Resection CAP Synoptic Pathology Report


name: DNA Mismatch Repair Biomarker Reporting CAP Synoptic Pathology Report


name: Problem Identified during Non-Clinical Procedure